

We claim:

1. A modified insulinotropic peptide or derivative thereof comprising a reactive group which reacts with amino groups, hydroxyl groups or thiol groups on blood components to form a stable covalent bond.  
5
2. The peptide of claim 1 wherein said reactive group is selected from the group consisting of succinimidyl and maleimido groups.
- 10 3. A peptide according to claim 2, wherein the derivative is reactive with a thiol group on a blood protein.
4. A peptide according to claim 1 wherein the peptide is selected from the group consisting of SEQ ID NO:2 SEQ ID NO:3, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:14 and SEQ ID NO:15.  
15
5. A peptide according to claim 1 wherein the peptide is selected from the group consisting of SEQ ID:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21 and SEQ ID NO:22.  
20
6. A composition comprising a derivative of insulinotropic peptide or analog thereof, said derivative comprising a reactive group which reacts with amino groups, hydroxyl groups or thiol groups on blood components to form stable covalent bonds wherein said reactive group is selected from the group consisting of succinimidyl and maleimido groups for use in a method of treating diabetes in a human.  
25
7. The composition of claim 6 wherein said derivative is reactive with blood components.  
30

8. The composition of claim 6 wherein said peptide is selected from the group consisting of SEQ ID NO:2 SEQ ID NO:3, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:14 and SEQ ID NO:15.

5

9. The composition of claim 6 wherein said peptide is selected from the group consisting of SEQ ID:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21 and SEQ ID NO:22.

10

10. A derivative of an insulinotropic peptide, said derivative comprising a maleimido group which reacts with a thiol group on human serum albumin to form a covalent bond.

15

11. The derivative of claim 9 wherein said peptide is selected from the group consisting of SEQ ID NO:2 SEQ ID NO:3, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:14 and SEQ ID NO:15.

20

12. The derivative of claim 9 wherein said peptide is selected from the group consisting of SEQ ID:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21 and SEQ ID NO:22.

25

13. A composition comprising a derivative of an insulinotropic peptide, said derivative comprising a maleimido group which reacts with a thiol group on human serum albumin to form a covalent bond for use in a method of treating diabetes in a human.

30

14. The composition of claim 13 wherein the peptide is selected from the group consisting of SEQ ID NO:2 SEQ ID NO:3, SEQ ID

NO:11, SEQ ID NO:13, SEQ ID NO:14 and SEQ ID NO:15.

15. The compositions of claim 13 wherein the peptide is selected  
from the group consisting of SEQ ID:16, SEQ ID NO:17, SEQ ID  
5 NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21 and SEQ  
ID NO:22.

16. Use of a composition for the manufacturer of a medicament  
extending the *in vivo* half-life of an insulinotropic peptide in a diabetes  
10 patient the composition comprising a derivative of an insulinotropic  
peptide or analog thereof, said derivative comprising a reactive group  
which reacts with amino groups, hydroxyl groups, or thiol groups on  
blood components to form stable covalent bonds, wherein the reactive  
group is selected from the group consisting of succinimidyl and  
15 maleimido groups.

17. Use of a composition according to claim 16, wherein the  
derivative is reacted with blood proteins.

20 18. Use of the composition of claim 16 wherein said peptide is  
selected from the group consisting of SEQ ID NO:2 SEQ ID NO:3, SEQ  
ID NO:11, SEQ ID NO:13, SEQ ID NO:14 and SEQ ID NO:15.

19. An insulinotropic peptide selected from the group consisting of  
25 GLP-1(1-36)-Lys<sup>37</sup>(ε-MPA)-NH<sup>2</sup>, GLP-1(1-36)-Lys<sup>37</sup>(ε-AEEA-AEEA-  
MPA)-NH<sup>2</sup>, GLP-1(7-36)-Lys<sup>37</sup> (ε-MPA)-NH<sup>2</sup>, GLP-1(7-36)-Lys<sup>37</sup> (ε-  
AEEA-AEEA-MPA)-NH<sup>2</sup>, D-Ala<sup>2</sup> GLP-1(7-36)-Lys<sup>37</sup>-(ε-MPA)-NH<sup>2</sup>, D-Ala<sup>2</sup>  
GLP-1(7-36)-Lys<sup>37</sup> (ε-AEEA-AEEA-MPA)-NH<sup>2</sup>, exendin-4 (1-39)-Lys<sup>40</sup> (ε-  
MPA)-NH<sup>2</sup>, exendin-4(1-39)-Lys<sup>40</sup> (ε-AEEA-AEEA-MPA)-NH<sup>2</sup>, exendin-  
30 3(1-39)-Lys<sup>40</sup> (ε-MPA)-NH<sup>2</sup> and exendin-3(1-39)-Lys<sup>40</sup> (ε-AEEA-AEEA-

MPA).